Objective: To assess the differences in the clinical and therapeutic management of early and established rheumatoid arthritis (RA) in clinical practice.
Methods: Retrospective and multicentre study including 360 patients diagnosed with RA. During the 12 months prior to the study, onset, sociodemographic, clinical and therapeutic data were collected by clinical chart review.
Results: A total of 152 patients with early RA and 208 with established RA were studied. 97.5% had received disease-modifying anti-rheumatic drugs (DMARDs) and 43.6% a TNFa blocker between the diagnosis and the start of the study. Established RA patients used TNFa blockers more frequently than early RA patients (60,1% vs 21,1%, p<0,001). Methotrexate was the most commonly used drug (70.6%). A treatment change was seen in 79% of patients with early RA and 60.6% of those with established RA. A dose change was the most frequent modification and an inadequate response the most frequent reason. A 25.8% of treatments were stopped due to adverse events. The mean (SD) decrease on DAS28 score was 0.9 (1.5) on early RA and 0.2 (1.0) on established RA patients. A 35.8% of early RA patients showed a good EULAR response, while only 16.2% among established RA patients (p<0.001). Rheumatoid factor and radiological progression assessment were the most requested determinations in early RA (p<0.05).
Conclusions: Spanish rheumatologists used biological drugs with a higher frequency in patients with more advanced disease, as recommended in the main clinical practice guidelines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.reuma.2010.08.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinary biomarkers of preeclampsia: An update.
Adv Clin Chem
January 2025
Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. Electronic address:
Preeclampsia (PE), a pregnancy-related syndrome, has motivated extensive research to understand its pathophysiology and develop early diagnostic methods. 'Omic' technologies, focusing on genes, mRNA, proteins, and metabolites, have revolutionized biological system studies. Urine emerges as an ideal non-invasive specimen for omics analysis, offering accessibility, easy collection, and stability, making it valuable for identifying biomarkers.
View Article and Find Full Text PDFc-FLIP/Ku70 complex; A potential molecular target for apoptosis induction in hepatocellular carcinoma.
Arch Biochem Biophys
January 2025
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address:
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide and the most common form of liver cancer. Despite global efforts toward early diagnosis and effective treatments, HCC is often diagnosed at advanced stages, where conventional therapies frequently lead to resistance and/or high recurrence rates. Therefore, novel biomarkers and promising medications are urgently required.
View Article and Find Full Text PDFCan microbiota gut-brain axis reverse neurodegenerative disorders in human?
Ageing Res Rev
January 2025
Medical Science and Technology Innovation Center, Shandong Key Laboratory of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, Shandong 250117, P R China; School of Medicine and Allied Health Sciences, University of The Gambia; Department of Medical Microbiology, Central South University Changsha, Hunan Provinces, China. Electronic address:
The trillions of microbial populations residing in the gut have recently shown that they can be used as a remedy for various diseases. The gut microbiota-brain-axis interface is one unique pathway that the microbiota demonstrates its medicinal value. This medicinal value is further seen when there is a decline in gut microbial diversity (dysbiosis).
View Article and Find Full Text PDFAdvances in our understanding of the estrous cycle and applications for improving targeted reproductive management in livestock.
Domest Anim Endocrinol
January 2025
USDA, ARS, U.S. Meat Animal Research Center, Clay Center, NE, USA.
The scientific discipline of endocrinology has been invaluable to our understanding of the estrous cycle. In the second half of the twentieth century the development of immunoassay technologies provided a rapid and sensitive method to quantify circulating concentrations of reproductive hormones and relate them to stage of the estrous cycle and physiological status of the animal. Ovarian ultrasonography provided the ability to track the growth and regression of ovarian structures within the same animal across the estrous cycle in real time and, in combination with hormonal profiling, accurately identify mechanisms regulating the estrous cycle and early pregnancy.
View Article and Find Full Text PDFCirculating tumour DNA in predicting and monitoring survival of patients with locally advanced rectal cancer undergoing multimodal treatment: long-term results from a prospective multicenter study.
EBioMedicine
January 2025
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. Electronic address:
Background: Neoadjuvant chemoradiotherapy (nCRT) is the standard for locally advanced rectal cancer (LARC). However, distant metastasis remains the primary cause of treatment failure. Early identification of high-risk individuals for personalized treatment may offer a solution.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!